American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Tallman
    Tallman
  5. Perales
    Perales
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Kernan
    Kernan
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (3844)
  2. Hematologic Malignancies, Division of (3639)
  3. Center for Hematologic Malignancies (3542)
  4. GSK Faculty (1553)
  5. Adult Leukemia (1289)
  6. Sloan Kettering Institute Faculty (1065)
  7. Bone Marrow Transplant (936)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (931)
  9. Lymphoma (898)
  10. Tow Center for Developmental Oncology (TCDO) (863)
Search Within
Formats
  1. Meeting Abstract (3939)
  2. Journal Article (1239)
  3. Research Letter (44)
  4. Review (44)
  5. Editorial (34)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (3844)
  2. Hematologic Malignancies, Division of (3639)
  3. Center for Hematologic Malignancies (3542)
  4. GSK Faculty (1553)
  5. Adult Leukemia (1289)
  6. Sloan Kettering Institute Faculty (1065)

More Groups

People
  1. Sergio Giralt (337)
  2. Andrew Zelenetz (328)
  3. Ross Levine (312)
  4. Martin Tallman (298)
  5. Miguel-Angel Perales (292)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (43)
  2. 2024 (217)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (4951)
  2. Blood Advances (322)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5323)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Practice patterns inform patient-centered approaches for the integration of BTK inhibitors in frontline mantle cell lymphoma
    Meeting Abstract

    Graham, T.; Ackbarali, T.; Kumar, A.; Matasar, M.
    Blood (2024)

    Fulltext@MSK | Save
  • Characterization of skin response in patients with mycosis fungoides and sezary syndrome treated with mogamulizumab: A retrospective, real world cohort
    Meeting Abstract

    Christensen, R.; Stuver, R.; Dusza, S.; Epstein-Peterson, Z. D.; Ghione, P.; Horwitz, S.; Johnson, W. T.; Moskowitz, A.; Myskowski, P.; Pulitzer, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • POIESIS: A randomized, double-blind, placebo-controlled, multicenter, global phase 3 study of navtemadlin as add-on to ruxolitinib in JAK inhibitor-naive patients with myelofibrosis who have a suboptimal response to ruxolitinib
    Meeting Abstract

    Vachhani, P.; Rampal, R.; Bradley, T.; Harrison, C.; Jain, T.; Kuykendall, A. T.; Palandri, F.; Mascarenhas, J. O.; Al-Ali, H. K.; Passamonti, F.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world efficacy outcomes of ciltacabtagene autoleucel in relapsed refractory multiple myeloma: A with the CARTITUDE-1 trial
    Meeting Abstract

    Kamboj, I.; Chang, D. R. Y.; Habib, A.; Vegel, A.; Struble, E.; Shaikh, H.; Strouse, C.; Davis, J. A.; Rashid, A.; Graf, K.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Treatment patterns of immunoglobulin replacement therapy among patients with multiple myeloma in the United States: A real-world analysis
    Meeting Abstract

    Ida, F.; Ramakrishna, B.; Nasserinejad, K.; Radu, A.; Lawo, J. P.; Zhang, X.; Gardiner, D.; Yoon, L.; Shen, J.; Dabrowski, E. C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Defining the rates of cytokine release syndrome associated with talquetamab step-up doses
    Meeting Abstract

    Hamadeh, I. S.; Shekarkhand, T.; Rueda, C.; Firestone, R. S.; Wang, A. X.; Korde, N.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world safety and early efficacy of talquetamab in patients with heavily-pretreated relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B. A.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Efficacy of daratumumab, pomalidomide and dexamethasone compared to daratumumab, carfilzomib and dexamethasone in high risk relapsed multiple myeloma: multicenter real-world experience
    Meeting Abstract

    Magee, G.; Mansour, R.; Chang, M. R.; Atrash, S.; Ahmed, N.; Mushtaq, M. U.; Ouchveridze, E.; Abdallah, A.; Paul, B.; Green, K. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Comparison of acute kidney injury in patients with relapsed or refractory multiple myeloma following CAR T-cell and bispecific antibody therapies
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B. A.; Farzana, T.; Shaikh, A.; Latcha, S.; Gutgarts, V.; Jurgens, E. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Body mass index trajectory during triplet induction therapy: Clinical implications in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R. S.; Derkach, A.; Furberg, H.; Shekarkhand, T.; Rueda, C.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save